APA (7th ed.) Citation

Dharmalingam, M., Aravind, S. R., Thacker, H., Paramesh, S., Mohan, B., Chawla, M., . . . Barkate, H. (2020). Efficacy and Safety of Remogliflozin Etabonate, a New Sodium Glucose Co-Transporter-2 Inhibitor, in Patients with Type 2 Diabetes Mellitus: A 24-Week, Randomized, Double-Blind, Active-Controlled Trial. Drugs (New York, N.Y.), 80(6), 587-600. https://doi.org/10.1007/s40265-020-01285-0

Chicago Style (17th ed.) Citation

Dharmalingam, Mala, et al. "Efficacy and Safety of Remogliflozin Etabonate, a New Sodium Glucose Co-Transporter-2 Inhibitor, in Patients with Type 2 Diabetes Mellitus: A 24-Week, Randomized, Double-Blind, Active-Controlled Trial." Drugs (New York, N.Y.) 80, no. 6 (2020): 587-600. https://doi.org/10.1007/s40265-020-01285-0.

MLA (9th ed.) Citation

Dharmalingam, Mala, et al. "Efficacy and Safety of Remogliflozin Etabonate, a New Sodium Glucose Co-Transporter-2 Inhibitor, in Patients with Type 2 Diabetes Mellitus: A 24-Week, Randomized, Double-Blind, Active-Controlled Trial." Drugs (New York, N.Y.), vol. 80, no. 6, 2020, pp. 587-600, https://doi.org/10.1007/s40265-020-01285-0.